Targeted News Service

Efzimfotase Alfa Demonstrated Positive Results From Global Phase III Clinical Program in Hypophosphatasia
April 01, 2026

WILMINGTON, Delaware, April 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Efzimfotase alfa demonstrated positive results from global Phase III clinical program in hypophosphatasia

MULBERRY randomized, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and clinically meaningful improvement in bone health in treatment-naive pediatric patients

CHESTNUT randomized, open- . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form